SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Neurodegenerative Disease

PUBLISHER: Grand View Research | PRODUCT CODE: 2132442

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 2132442

Spasticity Treatment Market Size, Share & Trends Analysis Report By Drug Class (Skeletal Muscle Relaxants, Botulinum Neurotoxin Therapies), By Indication, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Spasticity Treatment Market Summary

The global spasticity treatment market size was valued at USD 1.6 billion in 2025 and is projected to grow from USD 1.7 billion in 2026 to USD 2.6 billion by 2033, at a CAGR of 6.2% from 2026 to 2033. North America dominated the market, accounting for the largest global share of 41.2% 2025. The market growth is driven by the increasing diagnosis of neurological disorders that commonly lead to muscle spasticity, including multiple sclerosis, cerebral palsy, stroke, traumatic brain injury, and spinal cord injury.

The growing aging population has contributed to a higher number of stroke survivors and patients with chronic neurological conditions requiring long-term spasticity management. Treatment continues to rely on a combination of oral medications, botulinum toxin injections, intrathecal baclofen therapy, physical rehabilitation, and surgical interventions based on disease severity and patient needs. Healthcare providers are placing greater emphasis on multidisciplinary care to improve mobility, reduce pain, prevent contractures, and enhance functional independence. The availability of advanced rehabilitation services, improved access to specialist neurology care, and increasing awareness of early intervention support treatment adoption across developed healthcare systems. At the same time, ongoing clinical research focused on novel neurotoxin formulations, improved drug delivery methods, and regenerative approaches is expanding future treatment possibilities while addressing the limitations associated with long-term symptom management.

Global Spasticity Treatment Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global spasticity treatment market report based on drug class, indication, route of administration, distribution channel, and region:

  • Drug Class Outlook (Revenue, USD Million/Billion, 2021 - 2033)
  • Skeletal Muscle Relaxants
  • Botulinum Neurotoxin Therapies
  • Benzodiazepines
  • Others
  • Indication Outlook (Revenue, USD Million/Billion, 2021 - 2033)
  • Multiple Sclerosis
  • Cerebral Palsy
  • Stroke
  • Spinal Cord Injury
  • Traumatic Brain Injury
  • Others
  • Route of Administration Outlook (Revenue, USD Million/Billion, 2021 - 2033)
  • Oral
  • Injectable
  • Intrathecal
  • Distribution Channel Outlook (Revenue, USD Million/Billion, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Regional Outlook (Revenue, USD Million/Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
Show more
Product Code: GVR-4-68041-003-6

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Indication
    • 1.2.3. Route of Administration
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Spasticity Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Spasticity Treatment Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2025 & 2033
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million/Billion)
  • 4.4. Skeletal Muscle Relaxants
    • 4.4.1. Skeletal Muscle Relaxants Market, 2021 - 2033 (USD Million/Billion)
  • 4.5. Botulinum Neurotoxin Therapies
    • 4.5.1. Botulinum Neurotoxin Therapies Market, 2021 - 2033 (USD Million/Billion)
  • 4.6. Benzodiazepines
    • 4.6.1. Benzodiazepines Market, 2021 - 2033 (USD Million/Billion)
  • 4.7. Others
    • 4.7.1. Others Market, 2021 - 2033 (USD Million/Billion)

Chapter 5. Spasticity Treatment Market: Indication Business Analysis

  • 5.1. Indication Market Share, 2025 & 2033
  • 5.2. Indication Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million/Billion)
  • 5.4. Multiple Sclerosis
    • 5.4.1. Multiple Sclerosis Market, 2021 - 2033 (USD Million/Billion)
  • 5.5. Cerebral Palsy
    • 5.5.1. Cerebral Palsy Market, 2021 - 2033 (USD Million/Billion)
  • 5.6. Stroke
    • 5.6.1. Stroke Market, 2021 - 2033 (USD Million/Billion)
  • 5.7. Spinal Cord Injury
    • 5.7.1. Spinal Cord Injury Market, 2021 - 2033 (USD Million/Billion)
  • 5.8. Traumatic Brain Injury
    • 5.8.1. Traumatic Brain Injury Market, 2021 - 2033 (USD Million/Billion)
  • 5.9. Others
    • 5.9.1. Others Market, 2021 - 2033 (USD Million/Billion)

Chapter 6. Spasticity Treatment Market: Route of Administration Business Analysis

  • 6.1. Route of Administration Market Share, 2025 & 2033
  • 6.2. Route of Administration Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million/Billion)
  • 6.4. Oral
    • 6.4.1. Oral Market, 2021 - 2033 (USD Million/Billion)
  • 6.5. Injectable
    • 6.5.1. Injectable Market, 2021 - 2033 (USD Million/Billion)
  • 6.6. Intrathecal
    • 6.6.1. Intrathecal Market, 2021 - 2033 (USD Million/Billion)

Chapter 7. Spasticity Treatment Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2025 & 2033
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million/Billion)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million/Billion)
  • 7.5. Retail Pharmacies
    • 7.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million/Billion)
  • 7.6. Online Pharmacies
    • 7.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million/Billion)

Chapter 8. Spasticity Treatment Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2025 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 8.4. North America
    • 8.4.1. North America Spasticity Treatment Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million/Billion)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. U.S. Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. Canada Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. Mexico Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.5. Europe
    • 8.5.1. Europe Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. UK Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. Germany Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement Framework
      • 8.5.4.5. France Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Reimbursement Framework
      • 8.5.5.5. Italy Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Target Disease Prevalence
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Reimbursement Framework
      • 8.5.6.5. Spain Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Target Disease Prevalence
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement Framework
      • 8.5.7.5. Denmark Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Target Disease Prevalence
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Reimbursement Framework
      • 8.5.8.5. Sweden Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Target Disease Prevalence
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Reimbursement Framework
      • 8.5.9.5. Norway Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. Japan Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. China Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Framework
      • 8.6.4.5. India Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Framework
      • 8.6.5.5. Australia Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Reimbursement Framework
      • 8.6.6.5. South Korea Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Target Disease Prevalence
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Reimbursement Framework
      • 8.6.7.5. Thailand Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.7. Latin America
    • 8.7.1. Latin America Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Target Disease Prevalence
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement Framework
      • 8.7.2.5. Brazil Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Target Disease Prevalence
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement Framework
      • 8.7.3.5. Argentina Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 8.8. Middle East and Africa
    • 8.8.1. Middle East and Africa Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Target Disease Prevalence
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Reimbursement Framework
      • 8.8.2.5. South Africa Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Target Disease Prevalence
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Reimbursement Framework
      • 8.8.3.5. Saudi Arabia Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Target Disease Prevalence
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Reimbursement Framework
      • 8.8.4.5. UAE Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Target Disease Prevalence
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Reimbursement Framework
      • 8.8.5.5. Kuwait Spasticity Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. AbbVie Inc.
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Ipsen S.A.
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Merz Therapeutics GmbH
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Eisai Co., Ltd.
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Teva Pharmaceutical Industries Ltd.
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. Viatris Inc.
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Amneal Pharmaceuticals, Inc.
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Sun Pharmaceutical Industries Ltd.
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Hikma Pharmaceuticals PLC
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Endo, Inc.
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives
Show more
Product Code: GVR-4-68041-003-6

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global spasticity treatment market, by region, 2021 - 2033 (USD Million/Billion)
  • Table 4 Global spasticity treatment market, by drug class, 2021 - 2033 (USD Million/Billion)
  • Table 5 Global spasticity treatment market, by indication, 2021 - 2033 (USD Million/Billion)
  • Table 6 Global spasticity treatment market, by route of administration, 2021 - 2033 (USD Million/Billion)
  • Table 7 Global spasticity treatment market, by distribution channel, 2021 - 2033 (USD Million/Billion)
  • Table 8 North America spasticity treatment market, by country, 2021 - 2033 (USD Million/Billion)
  • Table 9 North America spasticity treatment market, by drug class, 2021 - 2033 (USD Million/Billion)
  • Table 10 North America spasticity treatment market, by indication, 2021 - 2033 (USD Million/Billion)
  • Table 11 North America spasticity treatment market, by route of administration, 2021 - 2033 (USD Million/Billion)
  • Table 12 North America spasticity treatment market, by distribution channel, 2021 - 2033 (USD Million/Billion)
  • Table 13 U.S. spasticity treatment market, by drug class, 2021 - 2033 (USD Million/Billion)
  • Table 14 U.S. spasticity treatment market, by indication, 2021 - 2033 (USD Million/Billion)
  • Table 15 U.S. spasticity treatment market, by route of administration, 2021 - 2033 (USD Million/Billion)
  • Table 16 U.S. spasticity treatment market, by distribution channel, 2021 - 2033 (USD Million/Billion)
  • Table 17 Canada spasticity treatment market, by drug class, 2021 - 2033 (USD Million/Billion)
  • Table 18 Canada spasticity treatment market, by indication, 2021 - 2033 (USD Million/Billion)
  • Table 19 Canada spasticity treatment market, by route of administration, 2021 - 2033 (USD Million/Billion)
  • Table 20 Canada spasticity treatment market, by distribution channel, 2021 - 2033 (USD Million/Billion)
  • Table 21 Mexico spasticity treatment market, by drug class, 2021 - 2033 (USD Million/Billion)
  • Table 22 Mexico spasticity treatment market, by indication, 2021 - 2033 (USD Million/Billion)
  • Table 23 Mexico spasticity treatment market, by route of administration, 2021 - 2033 (USD Million/Billion)
  • Table 24 Mexico spasticity treatment market, by distribution channel, 2021 - 2033 (USD Million/Billion)
  • Table 25 Europe spasticity treatment market, by country, 2021 - 2033 (USD Million/Billion)
  • Table 26 Europe spasticity treatment market, by drug class, 2021 - 2033 (USD Million/Billion)
  • Table 27 Europe spasticity treatment market, by indication, 2021 - 2033 (USD Million/Billion)
  • Table 28 Europe spasticity treatment market, by route of administration, 2021 - 2033 (USD Million/Billion)
  • Table 29 Europe spasticity treatment market, by distribution channel, 2021 - 2033 (USD Million/Billion)
  • Table 30 UK spasticity treatment market, by drug class, 2021 - 2033 (USD Million/Billion)
  • Table 31 UK spasticity treatment market, by indication, 2021 - 2033 (USD Million/Billion)
  • Table 32 UK spasticity treatment market, by route of administration, 2021 - 2033 (USD Million/Billion)
  • Table 33 UK spasticity treatment market, by distribution channel, 2021 - 2033 (USD Million/Billion)
  • Table 34 Germany spasticity treatment market, by drug class, 2021 - 2033 (USD Million/Billion)
  • Table 35 Germany spasticity treatment market, by indication, 2021 - 2033 (USD Million/Billion)
  • Table 36 Germany spasticity treatment market, by route of administration, 2021 - 2033 (USD Million/Billion)
  • Table 37 Germany spasticity treatment market, by distribution channel, 2021 - 2033 (USD Million/Billion)
  • Table 38 France spasticity treatment market, by drug class, 2021 - 2033 (USD Million/Billion)
  • Table 39 France spasticity treatment market, by indication, 2021 - 2033 (USD Million/Billion)
  • Table 40 France spasticity treatment market, by route of administration, 2021 - 2033 (USD Million/Billion)
  • Table 41 France spasticity treatment market, by distribution channel, 2021 - 2033 (USD Million/Billion)
  • Table 42 Italy spasticity treatment market, by drug class, 2021 - 2033 (USD Million/Billion)
  • Table 43 Italy spasticity treatment market, by indication, 2021 - 2033 (USD Million/Billion)
  • Table 44 Italy spasticity treatment market, by route of administration, 2021 - 2033 (USD Million/Billion)
  • Table 45 Italy spasticity treatment market, by distribution channel, 2021 - 2033 (USD Million/Billion)
  • Table 46 Spain spasticity treatment market, by drug class, 2021 - 2033 (USD Million/Billion)
  • Table 47 Spain spasticity treatment market, by indication, 2021 - 2033 (USD Million/Billion)
  • Table 48 Spain spasticity treatment market, by route of administration, 2021 - 2033 (USD Million/Billion)
  • Table 49 Spain spasticity treatment market, by distribution channel, 2021 - 2033 (USD Million/Billion)
  • Table 50 Norway spasticity treatment market, by drug class, 2021 - 2033 (USD Million/Billion)
  • Table 51 Norway spasticity treatment market, by indication, 2021 - 2033 (USD Million/Billion)
  • Table 52 Norway spasticity treatment market, by route of administration, 2021 - 2033 (USD Million/Billion)
  • Table 53 Norway spasticity treatment market, by distribution channel, 2021 - 2033 (USD Million/Billion)
  • Table 54 Denmark spasticity treatment market, by drug class, 2021 - 2033 (USD Million/Billion)
  • Table 55 Denmark spasticity treatment market, by indication, 2021 - 2033 (USD Million/Billion)
  • Table 56 Denmark spasticity treatment market, by route of administration, 2021 - 2033 (USD Million/Billion)
  • Table 57 Denmark spasticity treatment market, by distribution channel, 2021 - 2033 (USD Million/Billion)
  • Table 58 Sweden spasticity treatment market, by drug class, 2021 - 2033 (USD Million/Billion)
  • Table 59 Sweden spasticity treatment market, by indication, 2021 - 2033 (USD Million/Billion)
  • Table 60 Sweden spasticity treatment market, by route of administration, 2021 - 2033 (USD Million/Billion)
  • Table 61 Sweden spasticity treatment market, by distribution channel, 2021 - 2033 (USD Million/Billion)
  • Table 62 Asia Pacific spasticity treatment market, by country, 2021 - 2033 (USD Million/Billion)
  • Table 63 Asia Pacific spasticity treatment market, by drug class, 2021 - 2033 (USD Million/Billion)
  • Table 64 Asia Pacific spasticity treatment market, by indication, 2021 - 2033 (USD Million/Billion)
  • Table 65 Asia Pacific spasticity treatment market, by route of administration, 2021 - 2033 (USD Million/Billion)
  • Table 66 Asia Pacific spasticity treatment market, by distribution channel, 2021 - 2033 (USD Million/Billion)
  • Table 67 Japan spasticity treatment market, by drug class, 2021 - 2033 (USD Million/Billion)
  • Table 68 Japan spasticity treatment market, by indication, 2021 - 2033 (USD Million/Billion)
  • Table 69 Japan spasticity treatment market, by route of administration, 2021 - 2033 (USD Million/Billion)
  • Table 70 Japan spasticity treatment market, by distribution channel, 2021 - 2033 (USD Million/Billion)
  • Table 71 China spasticity treatment market, by drug class, 2021 - 2033 (USD Million/Billion)
  • Table 72 China spasticity treatment market, by indication, 2021 - 2033 (USD Million/Billion)
  • Table 73 China spasticity treatment market, by route of administration, 2021 - 2033 (USD Million/Billion)
  • Table 74 China spasticity treatment market, by distribution channel, 2021 - 2033 (USD Million/Billion)
  • Table 75 India spasticity treatment market, by drug class, 2021 - 2033 (USD Million/Billion)
  • Table 76 India spasticity treatment market, by indication, 2021 - 2033 (USD Million/Billion)
  • Table 77 India spasticity treatment market, by route of administration, 2021 - 2033 (USD Million/Billion)
  • Table 78 India spasticity treatment market, by distribution channel, 2021 - 2033 (USD Million/Billion)
  • Table 79 Australia spasticity treatment market, by drug class, 2021 - 2033 (USD Million/Billion)
  • Table 80 Australia spasticity treatment market, by indication, 2021 - 2033 (USD Million/Billion)
  • Table 81 Australia spasticity treatment market, by route of administration, 2021 - 2033 (USD Million/Billion)
  • Table 82 Australia spasticity treatment market, by distribution channel, 2021 - 2033 (USD Million/Billion)
  • Table 83 South Korea spasticity treatment market, by drug class, 2021 - 2033 (USD Million/Billion)
  • Table 84 South Korea spasticity treatment market, by indication, 2021 - 2033 (USD Million/Billion)
  • Table 85 South Korea spasticity treatment market, by route of administration, 2021 - 2033 (USD Million/Billion)
  • Table 86 South Korea spasticity treatment market, by distribution channel, 2021 - 2033 (USD Million/Billion)
  • Table 87 Thailand spasticity treatment market, by drug class, 2021 - 2033 (USD Million/Billion)
  • Table 88 Thailand spasticity treatment market, by indication, 2021 - 2033 (USD Million/Billion)
  • Table 89 Thailand spasticity treatment market, by route of administration, 2021 - 2033 (USD Million/Billion)
  • Table 90 Thailand spasticity treatment market, by distribution channel, 2021 - 2033 (USD Million/Billion)
  • Table 91 Latin America spasticity treatment market, by country, 2021 - 2033 (USD Million/Billion)
  • Table 92 Latin America spasticity treatment market, by drug class, 2021 - 2033 (USD Million/Billion)
  • Table 93 Latin America spasticity treatment market, by indication, 2021 - 2033 (USD Million/Billion)
  • Table 94 Latin America spasticity treatment market, by route of administration, 2021 - 2033 (USD Million/Billion)
  • Table 95 Latin America spasticity treatment market, by distribution channel, 2021 - 2033 (USD Million/Billion)
  • Table 96 Brazil spasticity treatment market, by drug class, 2021 - 2033 (USD Million/Billion)
  • Table 97 Brazil spasticity treatment market, by indication, 2021 - 2033 (USD Million/Billion)
  • Table 98 Brazil spasticity treatment market, by route of administration, 2021 - 2033 (USD Million/Billion)
  • Table 99 Brazil spasticity treatment market, by distribution channel, 2021 - 2033 (USD Million/Billion)
  • Table 100 Argentina spasticity treatment market, by drug class, 2021 - 2033 (USD Million/Billion)
  • Table 101 Argentina spasticity treatment market, by indication, 2021 - 2033 (USD Million/Billion)
  • Table 102 Argentina spasticity treatment market, by route of administration, 2021 - 2033 (USD Million/Billion)
  • Table 103 Argentina spasticity treatment market, by distribution channel, 2021 - 2033 (USD Million/Billion)
  • Table 104 Middle East & Africa spasticity treatment market, by country, 2021 - 2033 (USD Million/Billion)
  • Table 105 Middle East & Africa spasticity treatment market, by drug class, 2021 - 2033 (USD Million/Billion)
  • Table 106 Middle East & Africa spasticity treatment market, by indication, 2021 - 2033 (USD Million/Billion)
  • Table 107 Middle East & Africa spasticity treatment market, by route of administration, 2021 - 2033 (USD Million/Billion)
  • Table 108 Middle East & Africa spasticity treatment market, by distribution channel, 2021 - 2033 (USD Million/Billion)
  • Table 109 South Africa spasticity treatment market, by drug class, 2021 - 2033 (USD Million/Billion)
  • Table 110 South Africa spasticity treatment market, by indication, 2021 - 2033 (USD Million/Billion)
  • Table 111 South Africa spasticity treatment market, by route of administration, 2021 - 2033 (USD Million/Billion)
  • Table 112 South Africa spasticity treatment market, by distribution channel, 2021 - 2033 (USD Million/Billion)
  • Table 113 Saudi Arabia spasticity treatment market, by drug class, 2021 - 2033 (USD Million/Billion)
  • Table 114 Saudi Arabia spasticity treatment market, by indication, 2021 - 2033 (USD Million/Billion)
  • Table 115 Saudi Arabia spasticity treatment market, by route of administration, 2021 - 2033 (USD Million/Billion)
  • Table 116 Saudi Arabia spasticity treatment market, by distribution channel, 2021 - 2033 (USD Million/Billion)
  • Table 117 UAE spasticity treatment market, by drug class, 2021 - 2033 (USD Million/Billion)
  • Table 118 UAE spasticity treatment market, by indication, 2021 - 2033 (USD Million/Billion)
  • Table 119 UAE spasticity treatment market, by route of administration, 2021 - 2033 (USD Million/Billion)
  • Table 120 UAE spasticity treatment market, by distribution channel, 2021 - 2033 (USD Million/Billion)
  • Table 121 Kuwait spasticity treatment market, by drug class, 2021 - 2033 (USD Million/Billion)
  • Table 122 Kuwait spasticity treatment market, by indication, 2021 - 2033 (USD Million/Billion)
  • Table 123 Kuwait spasticity treatment market, by route of administration, 2021 - 2033 (USD Million/Billion)
  • Table 124 Kuwait spasticity treatment market, by distribution channel, 2021 - 2033 (USD Million/Billion)

List of Figures

  • Fig. 1 Spasticity treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Spasticity treatment market dynamics
  • Fig. 11 Spasticity treatment market: Porter's five forces analysis
  • Fig. 12 Spasticity treatment market: PESTLE analysis
  • Fig. 13 Drug Class market, 2021 - 2033 (USD Million/Billion)
  • Fig. 14 Skeletal muscle relaxants market, 2021 - 2033 (USD Million/Billion)
  • Fig. 15 Botulinum neurotoxin therapies market, 2021 - 2033 (USD Million/Billion)
  • Fig. 16 Benzodiazepines market, 2021 - 2033 (USD Million/Billion)
  • Fig. 17 Indication market, 2021 - 2033 (USD Million/Billion)
  • Fig. 18 Multiple sclerosis market, 2021 - 2033 (USD Million/Billion)
  • Fig. 19 Cerebral palsy market, 2021 - 2033 (USD Million/Billion)
  • Fig. 20 Stroke market, 2021 - 2033 (USD Million/Billion)
  • Fig. 21 Spinal cord injury market, 2021 - 2033 (USD Million/Billion)
  • Fig. 22 Traumatic brain injury market, 2021 - 2033 (USD Million/Billion)
  • Fig. 23 Others market, 2021 - 2033 (USD Million/Billion)
  • Fig. 24 Route of administration market, 2021 - 2033 (USD Million/Billion)
  • Fig. 25 Oral market, 2021 - 2033 (USD Million/Billion)
  • Fig. 26 Injectable market, 2021 - 2033 (USD Million/Billion)
  • Fig. 27 Intrathecal market, 2021 - 2033 (USD Million/Billion)
  • Fig. 28 Distribution channel market, 2021 - 2033 (USD Million/Billion)
  • Fig. 29 Hospital pharmacies market, 2021 - 2033 (USD Million/Billion)
  • Fig. 30 Retail pharmacies market, 2021 - 2033 (USD Million/Billion)
  • Fig. 31 Online Pharmacies market, 2021 - 2033 (USD Million/Billion)
  • Fig. 32 Spasticity treatment market revenue, by region
  • Fig. 33 Regional marketplace: Key takeaways
  • Fig. 34 North America spasticity treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 35 U.S. country dynamics
  • Fig. 36 U.S. spasticity treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 37 Canada country dynamics
  • Fig. 38 Canada spasticity treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 39 Mexico country dynamics
  • Fig. 40 Mexico spasticity treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 41 Europe spasticity treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 42 UK country dynamics
  • Fig. 43 UK spasticity treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 44 Germany country dynamics
  • Fig. 45 Germany spasticity treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 46 France country dynamics
  • Fig. 47 France spasticity treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 48 Italy country dynamics
  • Fig. 49 Italy spasticity treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 50 Spain country dynamics
  • Fig. 51 Spain spasticity treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 52 Norway country dynamics
  • Fig. 53 Norway spasticity treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 54 Sweden country dynamics
  • Fig. 55 Sweden spasticity treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 56 Denmark country dynamics
  • Fig. 57 Denmark spasticity treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 58 Asia Pacific spasticity treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 59 Japan country dynamics
  • Fig. 60 Japan spasticity treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 61 China country dynamics
  • Fig. 62 China spasticity treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 63 India country dynamics
  • Fig. 64 India spasticity treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 65 Australia country dynamics
  • Fig. 66 Australia spasticity treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 67 South Korea country dynamics
  • Fig. 68 South Korea spasticity treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 69 Thailand country dynamics
  • Fig. 70 Thailand spasticity treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 71 Latin America spasticity treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 72 Brazil country dynamics
  • Fig. 73 Brazil spasticity treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 74 Argentina country dynamics
  • Fig. 75 Argentina spasticity treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 76 MEA spasticity treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 77 South Africa country dynamics
  • Fig. 78 South Africa spasticity treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 79 Saudi Arabia country dynamics
  • Fig. 80 Saudi Arabia spasticity treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 81 UAE country dynamics
  • Fig. 82 UAE spasticity treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 83 Kuwait country dynamics
  • Fig. 84 Kuwait spasticity treatment market, 2021 - 2033 (USD Million/Billion)
  • Fig. 85 Company categorization
  • Fig. 86 Company market position analysis
  • Fig. 87 Strategic framework
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!